company background image
SLRX logo

Salarius Pharmaceuticals NasdaqCM:SLRX Stock Report

Last Price

US$0.49

Market Cap

US$2.1m

7D

-1.4%

1Y

-71.2%

Updated

20 Apr, 2024

Data

Company Financials +

Salarius Pharmaceuticals, Inc.

NasdaqCM:SLRX Stock Report

Market Cap: US$2.1m

SLRX Stock Overview

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need.

SLRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Salarius Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Salarius Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.49
52 Week HighUS$2.31
52 Week LowUS$0.43
Beta1
1 Month Change-15.72%
3 Month Change-17.46%
1 Year Change-71.16%
3 Year Change-98.38%
5 Year Changen/a
Change since IPO-99.83%

Recent News & Updates

Recent updates

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Oct 14

Salarius adds 12% after updates on clinical programs and financials

Sep 13

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Aug 22

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Aug 08

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Aug 02

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Jun 07

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

May 27

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Feb 09
Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Salarius Pharmaceuticals receives second installment of $1.7M in payments

Jan 13

Salarius Pharma raises $3.5M via warrant exercise

Dec 11

Salarius Pharmaceuticals EPS in-line, beats on revenue

Nov 11

Shareholder Returns

SLRXUS BiotechsUS Market
7D-1.4%-4.7%-3.7%
1Y-71.2%-2.7%20.2%

Return vs Industry: SLRX underperformed the US Biotechs industry which returned -2.7% over the past year.

Return vs Market: SLRX underperformed the US Market which returned 20.2% over the past year.

Price Volatility

Is SLRX's price volatile compared to industry and market?
SLRX volatility
SLRX Average Weekly Movement11.1%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: SLRX's share price has been volatile over the past 3 months.

Volatility Over Time: SLRX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a2David Arthurwww.salariuspharma.com

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.

Salarius Pharmaceuticals, Inc. Fundamentals Summary

How do Salarius Pharmaceuticals's earnings and revenue compare to its market cap?
SLRX fundamental statistics
Market capUS$2.13m
Earnings (TTM)-US$12.54m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLRX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$12.54m
Earnings-US$12.54m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.91
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio5.5%

How did SLRX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.